Local Infiltration with Ropivacaine for Postoperative Analgesia after Hip Fracture

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-005835-27-DK

Enrollment

100

Registered

2007-11-30

Start date

2008-01-10

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of local infiltration with ropivacaine for postoperative analgesia after hip fracture is evaluated.

Interventions

Trade Name: Naropine Product Name: Ropivacaine / Naropine Pharmaceutical Form: Solution for injection INN or Proposed INN: ROPIVACAINE CAS Number: 84057954 Other descriptive name: Naropin Concentratio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fractura pertrochanterica Fractura colli femoris Low energy trauma Intact cognitive status and ability to provide written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Refusal to participate in the study opioid or glucocorticoid therapy abuse of alcohol or other substances

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the effect of local infiltration with Ropivacaine for postoperative analgesia after hip fracture.;Secondary Objective: ;Primary end point(s): Postoperative analgesia with less side effects (confusion, nausea) as seen with traditional treatment of postoperative pain with opioids.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026